Kasturi Siddhanta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kasturi Siddhanta has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- David Oupický
University of Nebraska Medical Center
4 shared publications - Chinmay M. Jogdeo
University of Nebraska Medical Center 3 Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy Omaha, Nebraska
2 shared publications - Ekta Kapoor
University of Nebraska Medical Center 3 Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy Omaha, Nebraska
2 shared publications - Ling Ding
Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA
2 shared publications Neha Kumari
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
2 shared publications- Sudipta Panja
Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center 68198-5880. Omaha NE USA
2 shared publications
Latest Publications
- Open Access
- 26 January 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Spotlighting rising researcher Kasturi Siddhanta: Development of inhalable and parenteral platforms for lung-targeted delivery of oligonucleotides- from microRNAs to self-amplifying RNAs
- 26 January 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Open AccessSpotlighting rising researcher Kasturi Siddhanta: Development of inhalable and parenteral platforms for lung-targeted delivery of oligonucleotides- from microRNAs to self-amplifying RNAs
- Open Access
- 11 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Macrocyclic Ionizable Lipids for Selective Lung Delivery of mRNA and Gene Recombination
Systemically administered lipid nanoparticles (LNPs) predominantly target the liver, limiting their use for extrahepatic applications. Here, we introduce cyclam-based ionizable lipids that confer selective lung tropism after intravenous dosing. A ten-member library spanning three linker chemotypes and varied hydrophobic tails produced LNPs that consistently delivered mRNA to the lung. Lipids with aromatic linkers yielded compact nanoparticles (50–80 nm), with high encapsulation and RNA recovery, and outperformed DLin-MC3-DMA in vitro and in vivo. In Ai9 reporter mice, two intravenous doses of Cre mRNA formulated with lead cyclam lipid achieved ~30% lung editing with minimal off-organ activity. Structure–property analyses showed that increasing lipophilicity and aromatic content correlated inversely with particle size and positively with encapsulation, establishing design rules for macrocycle-guided delivery. Cyclam-based ionizable lipids thus enable systemically administered, lung-selective expression and provide a versatile platform for mRNA and gene-editing therapies.
- 11 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMacrocyclic Ionizable Lipids for Selective Lung Delivery of mRNA and Gene Recombination
Systemically administered lipid nanoparticles (LNPs) predominantly target the liver, limiting their use for extrahepatic applications. Here, we introduce cyclam-based ionizable lipids that confer selective lung tropism after intravenous dosing. A ten-member library spanning three linker chemotypes and varied hydrophobic tails produced LNPs that consistently delivered mRNA to the lung. Lipids with aromatic linkers yielded compact nanoparticles (50–80 nm), with high encapsulation and RNA recovery, and outperformed DLin-MC3-DMA in vitro and in vivo. In Ai9 reporter mice, two intravenous doses of Cre mRNA formulated with lead cyclam lipid achieved ~30% lung editing with minimal off-organ activity. Structure–property analyses showed that increasing lipophilicity and aromatic content correlated inversely with particle size and positively with encapsulation, establishing design rules for macrocycle-guided delivery. Cyclam-based ionizable lipids thus enable systemically administered, lung-selective expression and provide a versatile platform for mRNA and gene-editing therapies.
- Open Access
Inhalable Perfluorocarbon RNA Nanocapsules Bypass Immune Clearance While Targeting Lung Epithelial and Lung Tumor Cells
Inhalation RNA therapy offers to transform treatment of pulmonary diseases, yet mucus trapping, immune clearance, and navigation of heterogeneous lung tissue architecture still prevents RNA from reaching its target cells. Here, we develop perfluorocarbon (PFC) RNA nanocapsules that show negligible immune clearance, minimal inflammatory response, and efficient mucus transport, while passively homing to lung epithelial and tumor cells. After a single aerosolized dose in orthotopic lung metastasis model, more than 60% of tumor cells and most type II alveolar and bronchial epithelial cells internalized the nanocapsules, with observed pulmonary retention exceeding 48 h. The nanocapsule provoke negligible cytokine release, enabling repeated dosing. Treatment with therapeutic miR34-a suppresses metastatic outgrowth, potentiates anti-tumor immunity, and almost doubles median survival relative to control paclitaxel chemotherapy. By combining unique PFC disposition with RNA versatility, the delivery platform overcomes the main biological barriers for inhalable RNA medicines and opens a translatable path for treating diverse pulmonary diseases.
Open AccessInhalable Perfluorocarbon RNA Nanocapsules Bypass Immune Clearance While Targeting Lung Epithelial and Lung Tumor Cells
Inhalation RNA therapy offers to transform treatment of pulmonary diseases, yet mucus trapping, immune clearance, and navigation of heterogeneous lung tissue architecture still prevents RNA from reaching its target cells. Here, we develop perfluorocarbon (PFC) RNA nanocapsules that show negligible immune clearance, minimal inflammatory response, and efficient mucus transport, while passively homing to lung epithelial and tumor cells. After a single aerosolized dose in orthotopic lung metastasis model, more than 60% of tumor cells and most type II alveolar and bronchial epithelial cells internalized the nanocapsules, with observed pulmonary retention exceeding 48 h. The nanocapsule provoke negligible cytokine release, enabling repeated dosing. Treatment with therapeutic miR34-a suppresses metastatic outgrowth, potentiates anti-tumor immunity, and almost doubles median survival relative to control paclitaxel chemotherapy. By combining unique PFC disposition with RNA versatility, the delivery platform overcomes the main biological barriers for inhalable RNA medicines and opens a translatable path for treating diverse pulmonary diseases.
- 13 March 2025
- Published by Elsevier in Biomaterials
- Vol. 320, 123255
Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer
- 13 March 2025
- Published by Elsevier in Biomaterials
- Vol. 320, 123255
Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer
- Open Access
- 16 December 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (7)
Advances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale‐up. This review highlights the advances of the last decade in lipid‐based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic‐based combinations for targeted therapy in cancer and inflammatory diseases.
- 16 December 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (7)
Open AccessAdvances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale‐up. This review highlights the advances of the last decade in lipid‐based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic‐based combinations for targeted therapy in cancer and inflammatory diseases.